Entrada Therapeutics, Inc. (NASDAQ:TRDA) Holdings Lifted by Wellington Management Group LLP

Wellington Management Group LLP increased its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 0.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,047,780 shares of the company’s stock after acquiring an additional 2,128 shares during the period. Wellington Management Group LLP owned about 3.14% of Entrada Therapeutics worth $15,811,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Strs Ohio increased its stake in shares of Entrada Therapeutics by 792.6% in the fourth quarter. Strs Ohio now owns 24,100 shares of the company’s stock worth $363,000 after acquiring an additional 21,400 shares during the last quarter. SG Americas Securities LLC grew its stake in Entrada Therapeutics by 27.7% in the fourth quarter. SG Americas Securities LLC now owns 11,714 shares of the company’s stock valued at $177,000 after purchasing an additional 2,540 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Entrada Therapeutics by 476.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,780 shares of the company’s stock worth $87,000 after purchasing an additional 4,777 shares during the last quarter. 86.39% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Dipal Doshi sold 1,800 shares of Entrada Therapeutics stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $15.00, for a total value of $27,000.00. Following the transaction, the chief executive officer now owns 338,575 shares of the company’s stock, valued at $5,078,625. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Dipal Doshi sold 1,800 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $15.00, for a total value of $27,000.00. Following the sale, the chief executive officer now directly owns 338,575 shares of the company’s stock, valued at $5,078,625. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Peter S. Kim acquired 2,276 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The shares were acquired at an average cost of $14.04 per share, with a total value of $31,955.04. Following the transaction, the director now directly owns 65,212 shares in the company, valued at approximately $915,576.48. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 13,475 shares of company stock worth $205,133. 7.58% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered their price target on Entrada Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday.

Entrada Therapeutics Trading Down 4.5 %

Entrada Therapeutics stock opened at $14.10 on Thursday. The company has a market capitalization of $476.02 million, a P/E ratio of 22.38 and a beta of -0.23. Entrada Therapeutics, Inc. has a 1-year low of $10.75 and a 1-year high of $18.44. The firm’s fifty day simple moving average is $14.49 and its 200-day simple moving average is $14.29.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Tuesday, May 7th. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of ($0.38) by $1.06. The company had revenue of $59.12 million for the quarter, compared to analyst estimates of $25.00 million. Entrada Therapeutics had a return on equity of 9.73% and a net margin of 14.42%. On average, equities research analysts predict that Entrada Therapeutics, Inc. will post -0.14 earnings per share for the current year.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.